Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy
- PMID: 11231363
- DOI: 10.1046/j.1523-1755.2001.0590031077.x
Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy
Abstract
Background: The IgA1 molecule, which is predominantly deposited in glomeruli in IgA nephropathy (IgAN), is a unique serum glycoprotein because it has O-glycan side chains in its hinge region. Our study was conducted to investigate the O-glycan structure in the glomerular IgA1 in IgAN.
Methods: The IgA1 was separated from 290 renal biopsy specimens of 278 IgAN patients and from four serum IgA1 samples (IgAN, 2; control, 2). The variety of O-glycan glycoform was determined by estimating the precise molecular weights of the IgA1 hinge glycopeptides using matrix-assisted laser desorption ionization time of flight mass spectrometry.
Results: The peak distribution of IgA1 hinge glycopeptides clearly shifted to lesser molecular weights in both glomerular and serum IgA1 in IgAN compared with the serum IgA1 of controls. In the five major peaks of IgA1 hinge glycopeptides in each sample, the numbers of carbohydrates composing O-glycans (GalNAc, Gal, and NANA) in the deposited and serum IgA1 in IgAN patients were significantly fewer than those in the serum IgA1 in the control groups.
Conclusion: The O-glycan side chains in the hinge of the glomerular IgA1 were highly underglycosylated in IgAN. These results indicate that the decreased sialylation and galactosylation of the IgA1 hinge glycopeptides play a crucial role in its glomerular deposition in IgAN.
Similar articles
-
O- and N-Glycosylation of Serum Immunoglobulin A is Associated with IgA Nephropathy and Glomerular Function.J Am Soc Nephrol. 2021 Oct;32(10):2455-2465. doi: 10.1681/ASN.2020081208. Epub 2021 Jun 14. J Am Soc Nephrol. 2021. PMID: 34127537 Free PMC article.
-
Direct evidence for decreased sialylation and galactosylation of human serum IgA1 Fc O-glycosylated hinge peptides in IgA nephropathy by mass spectrometry.Biochem Biophys Res Commun. 2000 Apr 29;271(1):268-74. doi: 10.1006/bbrc.2000.2613. Biochem Biophys Res Commun. 2000. PMID: 10777713
-
IgA nephropathy and aberrant glycosylation of tonsillar, serum and glomerular IgA1.Adv Otorhinolaryngol. 2011;72:68-70. doi: 10.1159/000324609. Epub 2011 Aug 18. Adv Otorhinolaryngol. 2011. PMID: 21865693 Review.
-
Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.J Am Soc Nephrol. 1998 Apr;9(4):577-82. doi: 10.1681/ASN.V94577. J Am Soc Nephrol. 1998. PMID: 9555659 Clinical Trial.
-
Methodological approaches to the analysis of IgA1 O-glycosylation in IgA nephropathy.J Nephrol. 1999 Mar-Apr;12(2):76-84. J Nephrol. 1999. PMID: 10378662 Review.
Cited by
-
Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy.Nephrol Dial Transplant. 2024 Aug 30;39(9):1494-1503. doi: 10.1093/ndt/gfae021. Nephrol Dial Transplant. 2024. PMID: 38271614 Free PMC article.
-
IgA subclasses have different effector functions associated with distinct glycosylation profiles.Nat Commun. 2020 Jan 8;11(1):120. doi: 10.1038/s41467-019-13992-8. Nat Commun. 2020. PMID: 31913287 Free PMC article.
-
Analysis of O-glycoforms of the IgA1 hinge region by sequential deglycosylation.Sci Rep. 2020 Jan 20;10(1):671. doi: 10.1038/s41598-020-57510-z. Sci Rep. 2020. PMID: 31959827 Free PMC article.
-
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy.Drugs. 2023 Nov;83(16):1475-1499. doi: 10.1007/s40265-023-01940-2. Epub 2023 Sep 25. Drugs. 2023. PMID: 37747686 Free PMC article. Review.
-
An Update on the Current State of Management and Clinical Trials for IgA Nephropathy.J Clin Med. 2021 Jun 4;10(11):2493. doi: 10.3390/jcm10112493. J Clin Med. 2021. PMID: 34200024 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous